Certolizumab pegol: a new biologic targeting rheumatoid arthritis.

Item

http://www.wikidata.org/entity/Q37676988

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh

2010年學術文章

@zh-hant

name

Certolizumab pegol: a new biologic targeting rheumatoid arthritis.

@en

Certolizumab pegol: a new biologic targeting rheumatoid arthritis.

@nl

type

Item

label

Certolizumab pegol: a new biologic targeting rheumatoid arthritis.

@en

Certolizumab pegol: a new biologic targeting rheumatoid arthritis.

@nl

prefLabel

Certolizumab pegol: a new biologic targeting rheumatoid arthritis.

@en

Certolizumab pegol: a new biologic targeting rheumatoid arthritis.

@nl

P1476

Certolizumab pegol: a new biologic targeting rheumatoid arthritis.

@en

P2093

Aarat M Patel

http://www.w3.org/2001/XMLSchema#string

Larry W Moreland

http://www.w3.org/2001/XMLSchema#string

P2860

IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats

Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious

The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense.

Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis.

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.

Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized cont

P304

855-866

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ECI.10.69

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2010-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20979550

http://www.w3.org/2001/XMLSchema#string

P932

3971417

http://www.w3.org/2001/XMLSchema#string